To Assessment the Digital Twin Technology in Pharmacotherapy

Read full text Summarise with VIRAT
Authors: A. Mumtaj Begam*, D. Aruna, S. Kokila, J. Maheswari, K. Maadevan, V. Tamilselvan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Digital Twin (DT) technology, introduced by Michael Grieves in 2002, creates dynamic virtual models of patients by integrating data from electronic health records, medical imaging, wearable sensors, genomics, and real-time physiological monitoring. Using artificial intelligence, machine learning, physics-based modeling, and big data analytics, DTs simulate disease progression, predict treatment responses, and support clinical decision-making. In healthcare, they enable personalized medicine, remote patient monitoring, and improved treatment planning for conditions such as cardiovascular diseases, cancer, orthopedic disorders, and type 1 diabetes. In drug development, DTs support clinical trial design, enable in-silico trials, and reduce costs and recruitment challenges. However, issues like data privacy, validation, ethical concerns, technological limitations, and regulatory uncertainty remain challenges. Overall, digital twin technology has strong potential to advance predictive, preventive, and personalized healthcare.

Fields of Study & Subjects

Artificial Intelligence in Healthcare and Education Technology and Human Factors in Education and Health Digital Transformation in Industry

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
26 March 2026
Language
EN